[Using parathyroid hormone 1-84 in the treatment of osteoporosis: presentation and comments of main clinical trial].
Osteoporosis and associated fractures associated constitute a real and serious socio-medical problem. The purpose of this research is to report the most important clinical studies regarding the effect of parathyroid hormone PTH 1-84 for osteoporosis. TOP study has demonstrated the antifracture effectiveness of PTH 1-84 in patients of primary prevention and particular attention has been paid to show a clear achievement of the primary end-point that consists in a reduction of the vertebral fracturing event. PATH study has evidenced that the administration for one year of alendronate after one year of PTH 1-84 reduced the risk of osteoporotic fractures. The primary endpoint has been the evaluation of the densitometry values in the femoral and lumbar side and the evaluation of markers of bone turnover. In this case it is possible to assume that the above mentioned therapy could offer benefits in the long term.
U.O. Medicina Interna, Ospedale S.M. Goretti, Latina, Italia.
R
R
Cesareo
C
C
Napolitano
M
M
Iozzino
F
F
Romitelli
G
G
Iarussi
M
M
Scona
B
B
De Rosa
D019386:Alendronate / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
D050071:Bone Density Conservation Agents; D010281:Parathyroid Hormone; D019386:Alendronate